Payment overview · 2025
General Payments
$2,468.00
106 reported records · 24 companies
Healthcare provider profile · identity verified
Martha E Lozano, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CHULA VISTA, CA · NPI 1609845627
Verified facts
What the public records show
CMS Open Payments records show Martha E Lozano, MD received $2,468.00 in general payments during 2025 across 106 reported records.
GlaxoSmithKline, LLC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ofev, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $755.55 | 30.6% | 31 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $345.26 | 14.0% | 16 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $202.91 | 8.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.64 | 7.4% | 8 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $143.45 | 5.8% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $118.47 | 4.8% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $99.68 | 4.0% | 4 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $99.27 | 4.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.07 | 2.8% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $53.13 | 2.1% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $44.58 | 1.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.76 | 1.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.56 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.11 | 1.5% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $34.22 | 1.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $30.85 | 1.2% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $29.47 | 1.2% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $25.57 | 1.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.03 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.05 | 0.9% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.22 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.58 | 0.7% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.75 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,433.24 | 104 |
| Education | $34.76 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $529.08 | 20 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $226.47 | 11 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $202.91 | 7 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $154.65 | 6 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $130.43 | 6 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $118.47 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $108.69 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $99.68 | 4 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $99.27 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $96.89 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $85.95 | 4 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.09 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.68 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.56 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $34.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Encore Normalized: encore |
Device | Philips North America LLC | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $18.04 | 2 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 512 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
512 | 186 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 857 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 165 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 514 | 189 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 512 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 119 |
| Metformin Hcl | Metformin Hcl | 428 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 106 |
| Omeprazole | Omeprazole | 241 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 71 |
| Nifedipine Er | Nifedipine | 208 | 62 |
| Prednisone | Prednisone | 205 | 102 |
| Montelukast Sodium | Montelukast Sodium | 193 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 62 |
| Simvastatin | Simvastatin | 181 | 51 |
| Gabapentin | Gabapentin | 155 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 62 |
| Breo Ellipta | Fluticasone/Vilanterol | 132 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 41 |
| Lisinopril | Lisinopril | 129 | 41 |
| Jardiance | Empagliflozin | 124 | 40 |
| Meloxicam | Meloxicam | 119 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 43 |
| Furosemide | Furosemide | 117 | 40 |
| Eliquis | Apixaban | 112 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 35 |
| Alprazolam | Alprazolam | 103 | 32 |
| Azithromycin | Azithromycin | 103 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 31 |
| Farxiga | Dapagliflozin Propanediol | 90 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 50 |
| Alendronate Sodium | Alendronate Sodium | 80 | 22 |
| Bumetanide | Bumetanide | 78 | 28 |
| Cefuroxime | Cefuroxime Axetil | 76 | 61 |
| Carvedilol | Carvedilol | 73 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 69 | 21 |
| Finasteride | Finasteride | 65 | 20 |
| Atenolol | Atenolol | 63 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Ofev | Nintedanib Esylate | 62 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 62 | 26 |
| Ibuprofen | Ibuprofen | 61 | 25 |
| Lorazepam | Lorazepam | 60 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 21 |
| Januvia | Sitagliptin Phosphate | 56 | 17 |
| Glimepiride | Glimepiride | 55 | 13 |
| Potassium Chloride | Potassium Chloride | 51 | 20 |
| Trazodone Hcl | Trazodone Hcl | 49 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 17 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Folic Acid | Folic Acid | 44 | 16 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Allopurinol | Allopurinol | 40 | 13 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 12 |
| Valsartan | Valsartan | 38 | 13 |
| Acyclovir | Acyclovir | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 15 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 13 |
| Tramadol Hcl | Tramadol Hcl | 29 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Nystatin | Nystatin | 28 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 13 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Ozempic | Semaglutide | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 15 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,468.00 · 106 records | GlaxoSmithKline, LLC. | ACTHAR, AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, DAYBUE, DUPIXENT, ELIQUIS, Encore, FARXIGA, ISTURISA, JARDIANCE, JASCAYD, LUMRYZ, LUNA, MOUNJARO, NUCALA, NURTEC ODT, OFEV, OPSYNVI, Ohtuvayre, Prolastin-C Liquid, Respiratory, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, XOLAIR, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error